Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly

Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma

(2014) Luis Syro et al.   Hormones-International Journal of Endocrinology and Metabolism

Carcinomes et adénomes hypophysaires agressifs : mise au point et nouvelles options thérapeutiques

(2009) J.-C. Maïza et al.   ANNALES D ENDOCRINOLOGIE

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

(2009) C Hagen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Acromegaly pathogenesis and treatment

(2009) Shlomo Melmed   JOURNAL OF CLINICAL INVESTIGATION

USE OF TEMOZOLOMIDE IN AGGRESSIVE PITUITARY TUMORS

(2009) Safraz Mohammed et al.   NEUROSURGERY

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation

(2009) David J Moore et al.   BMC Endocrine Disorders

Clinicopathological Features of Growth Hormone-producing Pituitary Adenomas: Difference among Various Types Defined by Cytokeratin Distribution Pattern Including a Transitional Form

(2008) Abdulkader Obari et al.   ENDOCRINE PATHOLOGY

Lipodystrophy in Patients with Acromegaly Receiving Pegvisomant

(2008) Vivien S. Bonert et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM